最新消息 - MicroSigX Biotech Diagnostic Limited

「我们乐于与您分享我们的荣耀与故事。」

20251113-LoveXpress_01

MicroSigX Joins the LoveXpress SEN Carnival with Science, Smiles, and Purpose

MicroSigX proudly made its first appearance at the LoveXpress SEN Roller Skating Charity Competition cum Carnival, connecting with SEN families, educators, and community partners in a celebration of talent, inclusion, and shared understanding.

CUHK in FOCUS Features Founding Professors Advancing Autism and IBD Diagnosis Through the Gut

We’re proud to see our co-founders Prof Siew Ng and Prof Francis Chan featured for their pioneering gut microbiome research. Their work is transforming how we understand and detect autism and IBD through microbial screening and precision care.

MicroSigX celebrates Dr Raphaela Iris Lau_01

MicroSigX celebrates Dr Raphaela Iris Lau as a selected Young Scientist at the Hong Kong Laureate Forum 2025 🌟

We are proud to share that our colleague Dr Raphaela Iris Lau has been selected to join the Hong Kong Laureate Forum 2025, together with over 200 young scientists from more than 25 countries and regions.

Celebrating the Launch of MicroSigX Biotech Diagnostic Research Laboratory – Wan Chai_01

🎉 Celebrating the Launch of MicroSigX Biotech Diagnostic Research Laboratory – Wan Chai 🧬

A new chapter begins! Today, we officially launched our new research laboratory in Wan Chai, Hong Kong — a strategic expansion of MicroSigX Biotech Diagnostic, built to accelerate innovation and global impact through microbial science.

Global Scientific Recognition for M3CRC with Invited Presentation by Prof. Francis Chan at EHMSG 2025_01

Global Scientific Recognition for M3CRC with Invited Presentation by Prof. Francis Chan at EHMSG 2025

We’re proud to annouce that our Co-founder, Professor Francis Chan, was invited to present our multi-centre study of M3CRC in Asia at EHMSG 2025, Europe’s leading summit on microbiome and gastrointestinal health.

MicroSigX Awarded RAISe Funding to Advance First-in-Class Microbiome Diagnostics for IBD and ASD_00

MicroSigX Awarded RAISe+ Funding to Advance First-in-Class Microbiome Diagnostics for IBD and ASD

We’re proud to share that MicroSigX Biotech Diagnostic Limited, a spin-off from The Chinese University of Hong Kong (CUHK), has been awarded funding under the prestigious RAISe+ Scheme by the Innovation and Technology Commission (ITC) of the Hong Kong government.

A 150% Surge in IBD A First-in-Class Solution in Develoment

Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is projected to rise by 150% in Hong Kong between 2014 and 2034, with healthcare costs expected to exceed HK$400 million annually, according to an epidemiological study jointly led by The Chinese University of Hong Kong (CUHK)’s Faculty of Medicine (CU Medicine) and the University of Calgary.

From Innovation to Impact - Bridging Academia and Industry_00

From Innovation to Impact - Bridging Academia and Industry

Following her personal journey in Video Clip 1, this second clip captures Prof. Siew Ng’s engaging exchange with the moderator at the Asia Summit on Global Health (ASGH) — where she shares her perspective on translating academic innovation into real-world healthcare solutions.

From Clinic to Lab to Boardroom - A Journey of Impact_00

From Clinic to Lab to Boardroom - A Journey of Impact

We’re proud to spotlight our co-founder Prof. Siew Ng, who shared her inspiring career journey at the Asia Summit on Global Health (ASGH) — an event that brought together over 2,900 participants from 42 countries and regions.

Shaping the Future of Global MedTech Regulation_00

Shaping the Future of Global MedTech Regulation

We are proud to share our CEO Rachel Fan was invited as a distinguished panelist and speaker at the inaugural Hong Kong International Medical Device Regulatory Forum, co-hosted by the Faculty of Medicine, The Chinese University of Hong Kong and the Department of Health, HKSAR.

MicroSigX Advances M3CRC with New Data and China Launch Plans_00

MicroSigX Advances M3CRC with New Data and China Launch Plans

At DDW 2025, MicroSigX presented updated interim results from its international multicenter study on M3CRC, a novel microbial gene marker test for colorectal cancer screening. The data continues to show high sensitivity and specificity in detecting advanced neoplasia, reinforcing M3CRC’s potential to transform non-invasive screening.

MicroSigX M3CRC Test Acclaimed at DDW 2025 Offering New Hope for CRC Prevention_00

MicroSigX M3CRC Test Acclaimed at DDW 2025 Offering New Hope for CRC Prevention

We are excited to share that our plenary abstract presentation at Digestive Disease Week (DDW) 2025, delivered by CUHK research investigator Dr. Louis Ho Shing Lau, received overwhelming positive feedback and continuous enquiries from top researchers and clinicians worldwide. This recognition underscores the transformative potential of our microbiome-based diagnostic test, M3CRC.

Live from DDW 2025 - MicroSigX Unveils M3CRC Data with Global Implications_00

Live from DDW 2025 - MicroSigX Unveils M3CRC Data with Global Implications

(San Diego, 4 May 2025) Today at Digestive Disease Week (DDW) 2025, MicroSigX unveiled pivotal clinical data from its multi-center study across nine centers in the Asia-Pacific region on M3CRC, a microbiome-based diagnostic panel for colorectal cancer screening.

Co-founder Professor Siew Ng Pioneers in IBD Global Study Published in Nature_00

Co-founder Professor Siew Ng Pioneers in IBD Global Study Published in Nature

Congratulations to our co-founder, Professor Siew Ng, Croucher Professor in Medical Sciences at CUHK Medicine, Director of the Microbiota I-Center (MagIC), and New Cornerstone Investigator, on achieving another significant success!

MicroSigX's M3CRC Revolutionizes Colorectal Cancer Screening with Proven Success and Growing Recognition_00

MicroSigX's M3CRC Revolutionizes Colorectal Cancer Screening with Proven Success and Growing Recognition

We are thrilled to announce that our M3 bacterial gene-marker test has been recognized in the 2023 Joint Asian Pacific Association of Gastroenterology (APAGE) and Asian Pacific Society of Digestive Endoscopy (APSDE) clinical practice guidelines for diagnosing colorectal neoplasia, published in the British Medical Journal – Gut. This endorsement highlights M3CRC's exceptional sensitivity and reliability.

news-img-82x-1-p-1080

MicroSigX Announces Promising Early Results from a Groundbreaking Multicenter Study on M3CRC Colorectal Cancer Screening at DDW 2025

We are thrilled to announce the promising early results from our groundbreaking multicenter study on colorectal cancer screening, which will be presented at Digestive Disease Week (DDW) 2025, from May 3-6, in San Diego, USA.

news-img-122x-1-p-1080

We are MicroSigX - Transform lives with microbial diagnostics

We are thrilled to announce the launch of MicroSigX, a groundbreaking biotech diagnostics company co-founded by Prof. Siew Ng and Prof. Francis Chan of the Faculty of Medicine, The Chinese University of Hong Kong.